discomfort associated with climacteric syndrome, in a low dose in order to minimize the risk of appearance of side effects, such as breast cancer.

Another object of the invention is to provide an effective pharmaceutical formulation for hormonal therapy in women with uterus to treat the symptomatology and discomfort associated with climacteric syndrome, in ultra-low doses in order to minimize the risk of undesirable effects such as breast cancer.

An additional object of this invention is to provide a pharmaceutical compound or formulation that can be applied parenterally, that is to say, in an intramuscular or subcutaneous manner.

Summary

In one aspect, there is provided a parenteral pharmaceutical formulation in suspension, of sustained release, containing suspended estradiol and progesterone particles for hormonal replacement in female mammals in low and ultra-low dose, in the form of an injectable suspension formed by estradiol particles, progesterone particles, a surfactant agent, an isosmotic agent, a viscous increasing agent and one or more preservatives.

Brief description of the Drawings

Figure 1 is a graphic of an evaluation of hot flashes per month in a period of six months.

Figure 2 is a relative graphic of the evolution of hot flashes during the 6 months of the analysis (severe hot flashes).

Figure 3 is a graphic related to the evolution of hot flashes during the 6 months of the analysis (moderate hot flashes).